Skip to main content
Premium Trial:

Request an Annual Quote

Abbott Obtains Rights to Distribute Biofortuna HLA-typing Kits

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Abbott has obtained the rights to distribute freeze-dried HLA-typing kits from Biofortuna as part of an agreement announced today.

Under the terms of the deal, Biofortuna will design, develop, and manufacture a range of the kits called SSPGo. Upon regulatory approvals, Abbott will have exclusive distribution rights in the US and all other geographies, excluding France, Spain, Portugal, and the Benelux countries. Along with SSPGo products, interpretation software called Verdict, kit updates, and improvements are covered by the deal.

Financial terms were not disclosed.

Biofortuna, a molecular diagnostics firm based in Liverpool, UK, which said in February it had raised about $1.6 million, has freeze-drying capabilities that result in diagnostic kits that are stable at ambient temperature for up to 16 months. This eliminates the need for refrigerators, freezers, and temperature-controlled shipping.

The SSPGo products are the firm's first freeze-dried HLA typing kits of its kind, Biofortuna said, and will be available to laboratories outside the US and for order from Abbott starting in June. The kits are CE-marked and have been submitted for approval by the US Food and Drug Administration.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.